The Pharma Legal Handbook

Turkey

Regulatory, Pricing and Reimbursement Overview \cdot Preclinical and Clinical Trial Requirements \cdot Marketing, Manufacturing, Packaging and Labeling Advertising \cdot Traditional Medicines and OTC Products \cdot Product Liability \cdot Patents and Trademarks \cdot Regulatory Reforms \cdot Orphan Drugs and Rare Diseases \cdot Localization \cdot Biosimilars and Biologics



Turkey

The Pharma Legal Handbook answers essential questions about this environment for pharmaceuticals in Turkey.

It is a must have for any company operating in the country or looking to enter the market.

Prepared in association with Moroğlu Arseven, a leading Turkish law firm, it should answer any questions linked to Regulation, Pricing, Clinical and Preclinical Trials, Marketing, Manufacturing, Trademarks and Patents.

PharmaBoardroom is not responsible for any mistakes contained within this publication. For specific advice on any legal issue, please contact a qualified professional.

Copyright: All rights reserved. No part of this publication maybe reproduced in any form or by any means, whether electronic, mechanical or otherwise including photocopying, recording or any information storage or retrieval system without prior written consent of PharmaBoardroom. While every attempt is made to ensure the accuracy of the information contained in this report, neither PharmaBoardroom nor the authors accept any liabilities for errors and omissions. Opinions expressed in this report are not necessarily those of the authors.

* THIS REPORT WAS ORIGINALLY PUBLISHED IN FEBRUARY 2019 AND THE INFORMATION CONTAINED WITHIN IS SUBJECT TO CHANGE.

**LAST UPDATE: JUNE 2022

MOROĞLU ARSEVEN

Moroğlu Arseven is a full-service law firm with broadly demonstrated expertise and experience in all aspects of business law. Established in 2000, the firm combines a new generation of experienced international business lawyers and acclaimed counsels who have academic, judicial and practical experience in private law. Its dynamic and dedicated team is able to analyse the legal framework and provide flexible solutions for clients doing business in Turkey. The firm serves local clients in international markets and international clients in Turkey. Clients appreciate the firm's responsive, clear and concise answers to legal questions, as well as its knowledge of their business goals, usually based on long relationships.

The firm represents and serves a diverse clientele, in a wide range of industries. In-depth sector knowledge ensures seamless service across practice areas, enabling Moroglu Arseven to meet all of a client's legal needs in Turkey. Key areas include pharmaceuticals, life sciences, manufacturing, retail, energy, banking and financial markets, construction, real estate, TMT and sports.

Moroğlu Arseven is known in Turkey as a detail oriented, well-connected, hands-on and concentrated law firm, as well as being expert at handling complex tasks, whether these tasks are related to transactions, disputes or settlements.

The firm has a dynamic and dedicated team of more than 50 lawyers, capable of communicating in English, French, German, and Turkish.

www.morogluarseven.com

A: Abdi İpekci Caddesi 19-1 Nişantaşı, 34367, Istanbul, Turkey

T: +90 212 377 47 00

F: +90 212 377 47 99



THE AUTHORS



DR. E. SEYFİ MOROĞLU, LL.M.

PARTNER

Seyfi's work includes all aspects of corporate, regulatory and dispute matters. He advises clients on a broad range of regulatory issues in different sectors, including pharmaceuticals, healthcare and life sciences. He has substantial expertise advising on comparative legal and functional issues, guiding international clients on how domestic legal issues will impact their global operations or commercial strategies. He has led many sensitive internal investigations, and regulatory investigations as well as regulatory disputes addressing issues such as import regime, mismanagement, capital market obligations, product liability, commercial liability, employee misconduct, and subsequent director or project-based consequences. He is consistently recognized as a leading individual in Turkey by Chambers & Partners, The Legal 500 and IFLR1000.

esmoroglu@morogluarseven.com



A. BAŞAK ACAR, LL.M.

SENIOR ASSOCIATE

Başak assists foreign and domestic companies with a full spectrum of corporate and commercial issues, as well as assists them to deal with day-to-day business obligations in Turkey. She also assists clients to deal with complicated regulatory compliance issues in Turkey. Her clients consists of domestic and international companies, most notably in the pharmaceuticals, healthcare, life sciences, agriculture, biotechnology, retail as well as consumer products and information technology sectors.

bacar@morogluarseven.com



GÖKÇE İZGİ, LL.M.

PARTNER

Gökçe advises clients on a full range of intellectual property issues and transactions, including trademarks, unfair competition, industrial designs, patents, copyrights and domain names. She manages the trademark portfolios of large, multi-national brands and corporations, often arranging seizure processes for counterfeit products.

Gökçe has particular experience with prosecution of trademarks, patents, and designs, as well as international patent applications and licensing. She has successfully litigated numerous intellectual property matters for leading international companies, including complex trademark and industrial design infringement cases, design cancellation actions, and unfair competition matters. Gökçe often advises clients operating in regulated markets, such as pharmaceuticals and tobacco.

gizgi@morogluarseven.com



MERVE ALTINAY ÖZTEKİN

SENIOR ASSOCIATE

Merve supports clients with complex intellectual property disputes and litigation, as well as offers day-to-day advice about managing intellectual assets. She regularly assists clients to understand and navigate local regulatory rules, such as in the pharmaceutical sector, or for advertising and product liability. Merve specialises in helping clients to protect, enforce and commercialise their trademarks, patents and designs. She has successfully represented many well-known brands and patents, on both sides of high-stakes and complex intellectual property lawsuits.

maltinay@morogluarseven.com



MOROĞLU ARSEVEN



CONTENTS

REGULATORY, PRICING, AND REIMBURSEMI OVERVIEW	ENT Page 6
PRECLINICAL AND CLINICAL TRIAL REQUIREMENTS	Page 17
MARKETING, MANUFACTURING, PACKAGING LABELING, ADVERTISING	AND Page 23
TRADITIONAL MEDICINES AND OVER-THE-COUNTER PRODUCTS	Page 37
05 PRODUCT LIABILITY	Page 43
06 PATENTS AND TRADEMARKS	Page 47
REGULATORY REFORMS	Page 54
ORPHAN DRUGS AND RARE DISEASES	Page 56
09 LOCALIZATION	Page 63
BIOSIMILARS AND BIOLOGICS —	Page 66





REGULATORY, PRICING, AND REIMBURSEMENT OVERVIEW

- 1. What are the regulatory authorities with jurisdiction over drugs, biologicals, and medical devices in your country?
- 2. What is the regulatory framework for the authorization, pricing, and reimbursement of drugs, biologicals, and medical devices?
- 3. What are the steps to obtaining authorization to develop, test, and market a product?
- 4. What are the approximate fees for each authorization?
- 5. For how long are marketing authorizations/registrations valid? How are marketing authorizations/registrations renewed?
- 6. How does the authorization process differ between brand-name products and generic products? Are there differences for local manufacturers versus foreign-owned manufacturers?
- 7. How are combination products (drug + drug, drug + biologic, drug + device, biologic + device, drug + biologic + device) regulated?

- 8. How is compliance with regulation monitored and evaluated? Is the regulatory regime comparable with the U.S. Food and Drug Administration or the European Medicines Agency expectations and requirements?
- 9. What is the potential range of penalties for noncompliance?
- 10. Is there a national healthcare system? If so, how is it administered and funded?
- **11.** How does the government (or public) healthcare system function with private sector healthcare?
- 12. Are prices of drugs and devices regulated and, if so, how?
- 13. How are drugs and devices used by patients paid for? What roles do public and private payers play?
- **14.** Who dispenses drugs and devices to patients and how are those dispensers compensated?
- 15. What are the professional and legal responsibilities of those who dispense drugs and devices? What role do they play in providing patient care, information, and safety?



REGULATORY, PRICING, AND REIMBURSEMENT OVERVIEW

1. What are the regulatory authorities with jurisdiction over drugs, biologicals, and medical devices in your country?

Turkey's Ministry of Health ("Ministry") is the main regulatory and responsible authority for drugs, biologicals and medical devices.

Regulatory authorities with jurisdiction over drugs, biologicals and medical devices in Turkey are the:

- Ministry of Health,
- Turkish Medicines and Medical Devices Agency ("TİTCK" "Türkiye İlaç ve Tibbi Cihaz Kurumu")
- Social Security Institution.

2. What is the regulatory framework for the authorization, pricing, and reimbursement of drugs, biologicals, and medical devices?

There are various regulations on authorization, pricing and reimbursement of drugs, biologicals and medical devices in Turkey. In general, these are based on the Law on Pharmaceutical and Medical Preparations numbered 1262 published in the Turkish Official Gazette dated 26 May 1928 and numbered 898 (İspençiyari ve Tibbi Müstahzarlar Kanunu).

In addition to the main law, other regulations in this area include:

- Law on the Pharmacists and Pharmacies numbered 6197 published in the Turkish Official Gazette dated 24 December 1953 and numbered 8591 (Eczacilar ve Eczaneler Hakkında Kanun),
- Main Law on Medical Services numbered 3359 published in the Official Gazette dated 15 May 1987 and numbered 19461 (*Sağlık Hizmetleri Temel Kanunu*),
- Regulation on the Safety of Medicinal Product published in the Turkish Official Gazette dated 15 April 2014 and numbered 28973 (*İlaçların Güvenliliği Hakkında Yönetmelik*),
- Regulation on Pharmacists and Pharmacies published in the Turkish Official Gazette dated 12 April 2014 and numbered 28970 (*Eczacılar ve Eczaneler Hakkında Yönetmelik*),
- Council of Ministers Decree on the Pricing of Human Medicinal Products published in the Turkish Official Gazette dated 24 February 2017 and numbered 29989 (Beşeri Ürünlerin Fiyatlandırılmasına Dair Karar),
- Regulation on Manufacturing Plants for Human Medicinal Products published in the Turkish Official Gazette dated 21 October 2017 and numbered 30217 (Beşeri Tibbi Ürünler İmalathaneleri Yönetmeliği),
- Implementing Regulation for Labelling, Package Leaflet and Tracing of Human Medicinal Products published in the Turkish Official Gazette dated 25 April 2017 and numbered 30048 (Beşeri Tıbbi Ürünlerin Ambalaj Bilgileri, Kullanma Talimatı ve Takibi Yönetmeliği),



- Regulation on the Licensing of Human Medicinal Products published in the Turkish Official Gazette dated 11 December 2021 and numbered 31686 (Beşeri Tibbi Ürünler Ruhsatlandırma Yönetmeliği),
- Regulation on the Surveillance and Examination of Human Medicinal Products published in the Turkish Official Gazette dated 22 March 2005 and numbered 25763 (Beşeri Tibbi Ürünlerin Güvenliğinin İzlenmesi ve Değerlendirilmesi Hakkında Yönetmelik),
- Communiqué on the Pricing of Human Medicinal Products published in the Turkish Official Gazette dated 29 September 2017 and numbered 30195 (Beşeri Tibbi Ürünlerin Fiyatlandırılması Hakkında Tebliğ),
- Regulation on Promotion of Medicinal Products for Human Use published in the Turkish Official Gazette dated 3 July 2015 and numbered 29405 (Beşeri Tibbi Ürünlerin Tanıtım Faaliyetleri Hakkında Yönetmelik),
- Guidelines for the Labelling, Instructions and Tracing of Human Medicinal Products issued by Ministry of Health (Beşeri Tibbi Ürünlerin Ambalaj Bilgileri ve Kullanma Talimatına İlişkin Kılavuzlar),
- Regulation on Clinical Research for Medication and Biological Products published in the Turkish Official Gazette dated 13 April 2013 and numbered 28617 (İlaç ve Biyolojik Ürünlerin Klinik Araştırmaları Hakkında Yönetmelik),
- Regulation on Traditional Herbal Medical Products published in the Turkish Official Gazette dated 6 October 2010 and numbered 27721 (Geleneksel Bitkisel Tibbi Ürünler Yönetmeliği),
- Regulation on Clinical Research for Medical Devices published in the Turkish Official Gazette dated 6 September 2014 and numbered 29111 (Tibbi Cihaz Klinik Araştırmaları Yönetmeliği),
- Regulation on Sales, Advertisement and Promotion of Medicinal Devices published in the Turkish Official Gazette dated 15 May 2014 and numbered 29001 (*Tibbi Cihaz Satış, Reklam ve Tanıtım Yönetmeliği*),
- Regulation on Medical Devices published in the Turkish Official Gazette dated 7 June 2011 and numbered 27957 (*Tibbi Cihazlar Yönetmeliği*),
- Regulation on Test, Control and Calibration of Medical Devices published in the Turkish Official Gazette dated 25 May 2015 and numbered 29397 (Tibbi Cihazların Test, Kontrol ve Kalibrasyonu Hakkında Yönetmelik).
- Guideline on Good Pharmacovigilance Practices issued by Turkish Medicines and Medical Devices Agency (İyi Farmakovijilans Uygulamaları Kılavuzu)
- Guideline on Good Manufacturing Practices issued by Turkish Medicines and Medical Devices Agency (İyi İmalat Uygulamaları Kılavuzu)
- Guideline on Good Distribution Practices issued by Turkish Medicines and Medical Devices Agency (İyi Dağıtım Uygulamaları Kılavuzu)

Turkish texts and unofficial translations for some of these can be found at TİTCK's official website: https://www.titck.gov.tr/mevzuat



3. What are the steps to obtaining authorization to develop, test, and market a product?

Developing a medicinal product takes considerable time in Turkey. The Ministry requires strict criteria for each step during this process (testing, licensing or marketing).

The authorization process generally involves:

- Preliminary examination,
- Evaluation of application,
- Approval or denial of application,
- Receiving the authorization of sale.

Pharmaceutical products cannot be launched on the market before obtaining a license, which is granted by the Ministry. To obtain a license, an application must be made to the Ministry by submitting the documents listed under the Licensing Regulation on Medicinal Products.

Before submitting a license application, the applicant must conduct toxicological and pharmacological tests, as well as clinical trials. The Regulation on Clinical Research outlines the procedure for conducting clinical trials. The application procedure begins with submitting a clinical trial dossier simultaneously to both TİTCK and the Ethics Committee (appointed by the Ministry). The Ethics Committee submits its review and assessments to TİTCK. The approval process takes approximately 7 to 15 days. Following the Ethics Committee's assessment, TİTCK delivers a report to the Ministry within 30 days for administrative evaluation and approval.

Subsequently, to distribute the drug, the applicant must obtain marketing authorization, which is regulated under the Licensing Regulation on Medicinal Products. TİTCK is the responsible administrative body. To obtain marketing authorization, real persons or legal entities who are resident in Turkey must file an application to the Ministry, including the documents listed under the Licensing Regulation on Medicinal Products. When granting marketing authorizations, the Ministry considers whether (Article 16, Licensing Regulation on Medicinal Products):

- Efficacy of the envisaged usage conditions have been proved,
- The pharmaceutical's reliability has been proved,
- The quality has been displayed with adequate technical and pharmaceutical properties.

Real person(s) applying for marketing authorization must be graduates from pharmacy, medicine, or chemistry faculties, and be entitled to operate in these disciplines in Turkey. Legal person(s) applying for marketing authorization must employ a person who meets these criteria (Article 7, Licensing Regulation on Medicinal Products).

If a medicinal product will be imported into Turkey or manufactured under license, the following certificates (issued by the license owner of the medicinal product) must be obtained from the local marketing authorities abroad and submitted to TİTCK with Turkish translations (Article 8, Licensing Regulation on Medicinal Products):

